RS50754B - Upotreba t-kadherina kao ciljnih struktura - Google Patents

Upotreba t-kadherina kao ciljnih struktura

Info

Publication number
RS50754B
RS50754B RSP-2009/0221A RSP20090221A RS50754B RS 50754 B RS50754 B RS 50754B RS P20090221 A RSP20090221 A RS P20090221A RS 50754 B RS50754 B RS 50754B
Authority
RS
Serbia
Prior art keywords
disorder
cadherin
metabolic disorders
soluble
treatment
Prior art date
Application number
RSP-2009/0221A
Other languages
English (en)
Inventor
Christopher Hug
Harvey F. Lodish
Original Assignee
Whitehead Institute For Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute For Biomedical Research filed Critical Whitehead Institute For Biomedical Research
Publication of RS50754B publication Critical patent/RS50754B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)

Abstract

Rastvorljivi oblik T-kadherina za lečenje metaboličkog pormećaja, što je naznačeno time da je navedeni rastvorljivi oblik odabran iz grupe koja se sastoji od:a) polipeptida koji se sastoji od amino kiselina 23 do 292 iz SEQ ID NO. 1b) polipeptida koji se sastoji od fragmenta najmanje 250, 300, 350, 400, 450, 500, 550, 600 ili 650 amino kiselina pod (a)c) mutein pod (a) ili (b) što je naznačeno time da je sekvenca amino kiseline najmanje 90%, 95%, 96%, 98% ili 99% identična kao i najmanje jedna sekvenca pod (a) ili (b);d) mutein pod (a) ili (b) koji enkodira nukleinska kiselina koja dovodi do hibridizacije u komplement DNK sekvence koja enkodira (a) ili (b) pod veoma strogim uslovima; ie) mutein pod (a) ili (b) što je naznačeno time da su sve promene u sekvencama amino kiselina konzervativne supstitucije amino kiselina sekvenci amino kiselina pod (a) ili (b).Prijava sadrži još 1 zavisni patentni zahtev.
RSP-2009/0221A 2003-12-03 2004-12-02 Upotreba t-kadherina kao ciljnih struktura RS50754B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52695603P 2003-12-03 2003-12-03
PCT/US2004/040363 WO2005057222A2 (en) 2003-12-03 2004-12-02 Use of t-cadherin as a target

Publications (1)

Publication Number Publication Date
RS50754B true RS50754B (sr) 2010-08-31

Family

ID=34676687

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0221A RS50754B (sr) 2003-12-03 2004-12-02 Upotreba t-kadherina kao ciljnih struktura

Country Status (18)

Country Link
US (1) US20070212686A1 (sr)
EP (1) EP1701978B1 (sr)
JP (1) JP2007519894A (sr)
AT (1) ATE422506T1 (sr)
AU (1) AU2004297914A1 (sr)
CA (1) CA2546126A1 (sr)
CY (1) CY1109014T1 (sr)
DE (1) DE602004019451D1 (sr)
DK (1) DK1701978T3 (sr)
ES (1) ES2320139T3 (sr)
HR (1) HRP20090119T3 (sr)
IL (1) IL175862A (sr)
NO (1) NO20062975L (sr)
PL (1) PL1701978T3 (sr)
PT (1) PT1701978E (sr)
RS (1) RS50754B (sr)
SI (1) SI1701978T1 (sr)
WO (1) WO2005057222A2 (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177621B1 (en) 2006-01-10 2013-10-09 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
TWI481870B (zh) 2009-04-01 2015-04-21 Colgate Palmolive Co 用於軟組織疾病診斷及作為用於口腔保健干預的標靶之蛋白質生物標記
EP2414571B1 (en) 2009-04-01 2017-06-07 Colgate-Palmolive Company Menthol-derivative compounds and use thereof as oral and systemic active agents
TWI405565B (zh) 2009-04-01 2013-08-21 Colgate Palmolive Co 口腔用組成物之抗－骨質流失及抗－牙周附連喪失之功效
SG173744A1 (en) 2009-04-01 2011-09-29 Colgate Palmolive Co Anti-biofilm carbonate compounds for use in oral care compositions
GB201312010D0 (en) * 2013-07-04 2013-08-21 Univ Birmingham Receptor Agonists
WO2016100301A1 (en) * 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
CN115485554A (zh) * 2020-03-03 2022-12-16 国立大学法人信州大学 脂联素的定量方法以及用于该定量方法的分析用试剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1023445B1 (de) * 1997-10-15 2005-08-17 Pharis Biotec GmbH Cadherin derived growth factor und seine verwendung
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
AU759144B2 (en) * 1998-05-05 2003-04-03 Adherex Technologies Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6472367B1 (en) * 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
ATE304552T1 (de) * 2000-02-18 2005-09-15 Leangene Ab Methoden zur identifizierung von zusammensetzungen, die für die behandlung von fettleibigkeit nützlich sind, unter verwendung von foxc2
AU2001292658A1 (en) * 2000-09-13 2002-03-26 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
WO2002053726A2 (en) * 2001-01-02 2002-07-11 Hybrigenics Protein-protein interactions in adipocyte cells
US20060286035A1 (en) * 2003-04-29 2006-12-21 Cytos Biotechnology Ag Methods and compositions for modulating the interaction between adiponectin and its receptor
JP2007531512A (ja) * 2003-11-10 2007-11-08 エピゲノミクス アーゲー 婦人科細胞増殖障害の分析方法

Also Published As

Publication number Publication date
PL1701978T3 (pl) 2009-07-31
AU2004297914A1 (en) 2005-06-23
ES2320139T3 (es) 2009-05-19
JP2007519894A (ja) 2007-07-19
SI1701978T1 (sl) 2009-08-31
NO20062975L (no) 2006-06-26
WO2005057222A3 (en) 2006-02-23
ATE422506T1 (de) 2009-02-15
DE602004019451D1 (de) 2009-03-26
IL175862A (en) 2010-11-30
EP1701978B1 (en) 2009-02-11
US20070212686A1 (en) 2007-09-13
IL175862A0 (en) 2006-10-05
EP1701978A2 (en) 2006-09-20
CA2546126A1 (en) 2005-06-23
DK1701978T3 (da) 2009-04-06
CY1109014T1 (el) 2014-07-02
PT1701978E (pt) 2009-03-03
HRP20090119T3 (en) 2009-04-30
WO2005057222A2 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
HRP20090119T3 (en) Use of soluble t-cadherin for the treatment of metabolic disorders
MXPA03011558A (es) Compuestos para el tratamiento de desordenes metabolicos.
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200602324A (en) Tetrahydro-indazole cannabinoid modulators cross reference to related applications
WO2008030706A3 (en) Anti-myostatin antibodies
DK1928850T3 (da) Midler til forebyggelse og behandling af lidelser, der involverer modulering af RyR-receptorerne
TWI370325B (en) Positive photosensitive resin composition,relief pattern and solid camera element using it
EP1771188A4 (en) METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS, INSULINED DISEASES AND HYPERCHOLESTERINEMIA
TWI350373B (en) Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
ATE462697T1 (de) Bisaryl-sulfonamide
TW200741009A (en) Methods of modulating SMYD3 for treatment of cancer
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
DE602005027400D1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz
EP1751620A4 (en) PHOTOSENSITIVE RESIN COMPOSITION AND LCD USING THE SAME
FR2916659B1 (fr) Dispositif pour l'application ou la projection d'un materiau de densite elevee.
WO2007067737A3 (en) Methods and compositions for inhibiting hiv infection
ZA200803532B (en) Hexahydro-cycloheptapyrazole cannabinoid modulators
EP3856790A4 (en) ANTI-CD40 BINDING MOLECULES WITH MODIFIED CF DOMAINS AND THEIR THERAPEUTIC USES
AU2003221878A8 (en) G-protein coupled receptor ligands and methods
FI20050669A0 (fi) Laitteisto partikkeleiden, kuten lastun ja hakkeen, käsittelemiseksi, esim. seulomiseksi tai sirottelemiseksi
WO2006116660A3 (en) Methods of inhibiting a gpr23
FR2876586B1 (fr) Composition pour prevenir ou traiter le stress, notamment les bouffees de stress chronique et permanent
CR9479A (es) Moduladores canabinoides de tetrahidrotiopirano pirazol
GB2433935B (en) Compounds for treating diabetes and related disorders
TNSN06263A1 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders